September 3, 2024 03:27 PM EDT

Pfizer and Valneva say second Lyme booster led to 'strong' responses, target 2026 FDA submission

Nicole DeFeudis

Editor

Pfizer and Valneva said patients demonstrated “strong immune responses” after receiving a second booster dose of their experimental Lyme disease vaccine, supporting the case for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pfizer and Valneva say second Lyme booster led to 'strong' responses, target 2026 FDA submission

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

SEC probe of Illumina’s Grail deal targets sales forecasts, sources say

Pfizer tees up Phase 3 test in weight management — but in an unexpected area

Arbor Biotechnologies cuts early-stage discovery work, lays off staff

Sofinnova’s Jim Healy on ‘more rational market’ as four biotech startups near their IPOs

Post-Hoc: Big promises built Moderna. They might also be its undoing

Scorpion details early data on targeted breast cancer drug as it seeks to challenge Novartis, Roche

Pfiz­er and Val­ne­va say sec­ond Ly­me boost­er led to 'strong' re­spons­es, tar­get 2026 FDA sub­mis­sion

Editor

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Pfizer and Valneva say second Lyme booster led to 'strong' responses, target 2026 FDA submission